ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT2100 for the Treatment ...
ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA ...
Morningstar3 天
ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT2100 for the Treatment ...
ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that the U.S. Food ...
Nature1 年
Unshackling genetic medicines by enabling delivery beyond the liver
ReCode Therapeutics is developing genetic therapies for rare diseases by addressing a key barrier for the field: delivery to the right cells, and not just the liver. Lipid nanoparticles (LNPs ...
Global mRNA-based Vaccines and Therapeutics Market is expected to Grow at a decent CAGR ...
According to the American Cancer Society (2023), in general, about 10–15% of all lung cancers are SCLC, and about 80–85% are ...
来自MSN4 个月
ReCode to secure funds for cystic fibrosis gene correction treatments
ReCode Therapeutics is set to secure up to $15m in additional funding from the Cystic Fibrosis Foundation to enhance its gene correction research programme. The initiative, conducted in ...